Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Summary

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne

Timeline

Start

2022-02-10

Primary completion

2022-10-27

Completion

2023-04-06

Drugs

Indications